Dose-Response in Radionuclide Therapy

放射性核素治疗的剂量反应

• 批准号: 7102237
• 负责人: George Sgouros
• 金额: $ 39.38万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7102237
• 关键词: clinical research; lymphoma; model; neoplasm /cancer; radionuclide therapy

DESCRIPTION (provided by applicant): Targeted radionuclide therapy is being actively investigated as a potential cancer therapy modality. The relationship between absorbed dose and tumor response or normal organ toxicity is important in optimizing radionuclide therapy. Current understanding of this relationship is almost completely derived from external beam rather than radionuclide therapy experience. Using data derived from clinical radionuclide therapy studies we propose to evaluate the potential role of radionuclide dosimetry in trial design and tumor response or toxicity prediction. The following questions will be addressed by this proposal: 1. What is the relationship between estimated absorbed dose and tumor and normal organ response? 2. Does patient specific, 3-D imaging-based dosimetry provide an advantage over a simpler, standard phantom-based approach? 3. Does radiobiologic modeling that accounts for differences in absorbed dose rate and uniformity improve response prediction? 4. How does prior therapy influence hematologic toxicity and the dose-response relationship? Using 3D-ID, a patient-specific 3-D dosimetry package developed by the PI with previous NIH support, the following aims are proposed to address these questions 1. Incorporate radiobiologic modeling in 3D-ID to utilize and interpret dose-rate and spatial uniformity information in evaluating response probability. 2.1. Obtain dose-response relationships in thyroid disease patients treated with I-131. 2.2. Obtain dose-response relationships for non-Hodgkin's' lymphoma patients treated with nonmyeloablative Tositumomab (Bexxar; 131l-anti-CD20) and Ibritumomab Tiuxetan (Zevalin; 90Y-anti-CD20). 3. Compare dose-response relationships obtained by accounting for dose-rate, non-uniformity and patient-specific anatomy (i.e., using 3D-ID) with those obtained using a simpler, standard-phantom based methodology (OLINDA); in the NHL studies, evaluate the role of FL.T3 ligand in improving the dose-response relationship for hematologic toxicity. Dosimetry has been assumed to be the best predictor of response following radionuclide treatment. Standardized, rigorous dosimetric analyses of radionuclide therapy data are needed to evaluate this assumption, identify the level of complexity required and to understand how other factors can impact the absorbed dose vs response relationship.

描述（由申请人提供）： 靶向放射性核素治疗作为一种潜在的癌症治疗方式正在被积极研究。吸收剂量与肿瘤反应或正常器官毒性之间的关系对于优化放射性核素治疗非常重要。目前对这种关系的理解几乎完全来自外部束而不是放射性核素治疗经验。我们建议使用来自临床放射性核素治疗研究的数据来评估放射性核素剂量测定在试验设计和肿瘤反应或毒性预测中的潜在作用。该提案将解决以下问题： 1. 估计吸收剂量与肿瘤和正常器官反应之间的关系是什么？ 2. 针对特定患者、基于 3D 成像的剂量测定是否比更简单、基于标准体模的方法更具优势？ 3. 考虑吸收剂量率和均匀性差异的放射生物学模型是否可以改善反应预测？ 4. 既往治疗如何影响血液学毒性和剂量反应关系？使用 3D-ID（由 PI 在先前 NIH 支持下开发的患者特定 3-D 剂量测定包），提出以下目标来解决这些问题 1. 在 3D-ID 中纳入放射生物学模型，以利用和解释剂量率和空间评估响应概率的均匀性信息。 2.1.获得接受 I-131 治疗的甲状腺疾病患者的剂量-反应关系。 2.2.获得接受非清髓性 Tositumomab（Bexxar；131l-抗 CD20）和 Ibritumomab Tiuxetan（Zevalin；90Y-抗 CD20）治疗的非霍奇金淋巴瘤患者的剂量-反应关系。 3. 将通过考虑剂量率、不均匀性和患者特异性解剖结构（即使用 3D-ID）获得的剂量反应关系与使用更简单、基于标准模型的方法（OLINDA）获得的剂量反应关系进行比较；在 NHL 研究中，评估 FL.T3 配体在改善血液毒性剂量反应关系中的作用。剂量测定被认为是放射性核素治疗后反应的最佳预测指标。需要对放射性核素治疗数据进行标准化、严格的剂量分析来评估这一假设，确定所需的复杂程度，并了解其他因素如何影响吸收剂量与反应关系。